Home/Pipeline/NBI-921352

NBI-921352

Epilepsy

Phase 2Active

Key Facts

Indication

Epilepsy

Phase

Phase 2

Status

Active

Company

Neurocrine Biosciences

About Neurocrine Biosciences

Founded in 1992, Neurocrine Biosciences has evolved from a research-focused biotech into a successful commercial company with over $1.5 billion in annual revenue. Their expertise in neuroscience drug development has produced breakthrough treatments like INGREZZA for tardive dyskinesia and a promising pipeline including programs for Parkinson's disease, schizophrenia, and endometriosis. The company combines strong commercial execution with continued innovation in CNS therapeutics.

View full company profile

Therapeutic Areas

Neurology Psychiatry Movement Disorders Endocrinology Women's Health

Other Epilepsy Drugs

Drug	Company	Phase	Status
Soticlestat (TAK-935)	Takeda Pharmaceutical	Phase 3	Active
UCB4144	UCB	Phase 2	Active
Keppra (levetiracetam)	UCB	Approved	Commercial
Oxtellar XR®	Supernus Pharmaceuticals	Approved/Commercial	Marketed
ADX71149	Addex Therapeutics	Phase 2	Active (Partner-led)
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active